Given that GPX4 is therefore still the major pharmacological target to trigger ferroptosis using small molecule inhibitors, we treated a panel of human ABC-DLBCL (U2932, HBL1, TMD8) and GCB-DLBCL (SU-DHL4, SU-DHL7, SU-DHL8) cell lines with two chemically distinct GPX4 inhibitors, ML210 and RSL3. Here, GPX4 is linked to diffuse large B-cell lymphoma.